Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
35,136
Total Claims
$11.4M
Drug Cost
1,306
Beneficiaries
$8,701
Cost/Patient
Risk Score Breakdown 26/100
Score components are additive. Read full methodology
Peer Comparison vs. 18,720 Cardiology providers
+471%
Cost per patient vs peers
$8,701 vs $1,524 avg
+170%
Brand preference vs peers
36.9% vs 13.7% avg
Brand vs Generic
Brand: 12,890 claims · $9.8M
Generic: 22,035 claims · $1.6M
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Denosumab | 575 | $991K |
| Icosapent Ethyl | 2,010 | $935K |
| Evolocumab | 1,150 | $856K |
| Empagliflozin | 491 | $530K |
| Apixaban | 591 | $493K |
| Semaglutide | 347 | $412K |
| Pitavastatin Calcium | 653 | $369K |
| Dapagliflozin Propanediol | 305 | $341K |
| Rivaroxaban | 339 | $334K |
| Metformin Hcl | 71 | $334K |
| Fluticasone/Umeclidin/Vilanter | 367 | $286K |
| Sacubitril/Valsartan | 242 | $252K |
| Bempedoic Acid/Ezetimibe | 346 | $227K |
| Linaclotide | 287 | $221K |
| Dulaglutide | 173 | $217K |
Prescribing Profile
Patient Profile
77
Avg Age
57%
Female
1.29
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data